Fortress CEO/Chairman Rosenwald Buys 136,723 Shares for $252,583
FBIO sits 15% above its 52-week low of $1.64.
Summary
Fortress Biotech's CEO and chairman Lindsay Rosenwald bought 136,723 shares in the open market for $252,583 over Nov 17-19, 2026, lifting his direct stake to 4,723,564 shares. The move follows the CFO's $87,814 purchase over the same days and the Nov 13 Q3 report.
Key Events · Ownership and Investor Activity · FBIO
-
CEO/Chairman Open-Market Purchase
Lindsay A. Rosenwald bought 136,723 shares in three trades from Nov 17-19, 2026, for $252,583.16 total, at weighted-average prices of $1.7973, $1.9029 and $1.8584.
-
Stake Rises to 4.72 Million Shares
Direct ownership rose to 4,723,564 shares after the purchases, up from 4,651,332 before the first trade.
-
Second Insider Buying This Week
The purchases follow CFO David Jin's 47,605-share, $87,814 open-market buy over the same Nov 17-19 window, disclosed in a separate Form 4.
-
Timing After Q3 Results
Buying came after the Nov 13 Q3 filing showing $19.2 million of revenue, $152.2 million of cash and no parent-level debt following repayment of the Oaktree facility.
Analysis · FBIO · Life Sciences
Why it matters: the CEO, president and chairman put $252,583 of his own money into open-market purchases over three sessions, paying $1.80-$1.90 a share. That is real cash, not an option exercise. It also comes days after the Q3 report showed $19.2 million of quarterly revenue, $152.2 million of cash and no parent-level debt following the Oaktree repayment. For a micro-cap, the buying is a meaningful slice of the float, and it pairs with the CFO's separate $87,814 purchase over the same Nov 17-19 window — two senior insiders accumulating at the same time.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBIO was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59M. The 52-week trading range was $1.64 to $4.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.